| Literature DB >> 35433795 |
Mahsa Rezazadegan1, Fatemeh Mirjalili1, Yahya Jalilpiran2,3, Monireh Aziz4, Ahmad Jayedi5, Leila Setayesh6, Mir Saeed Yekaninejad7, Krista Casazza8, Khadijeh Mirzaei6.
Abstract
A dietary diversity score (DDS) may be a useful strategy for monitoring risks associated with chronic diseases. Few studies have investigated the relationship between DDS and the progression to chronic kidney disease (CKD). A better understanding of the relationship between DDS and diabetic nephropathy (DN) may provide insight for monitoring the overall diet and clinical outcomes. This case-control study included 105 women with DN and 105 controls with age and diabetes duration-matched to evaluate the extent to which DDS is associated with DN. Dietary intake was assessed using the food frequency questionnaire (FFQ). DDS was calculated based on the method using five food groups: bread/grains, vegetables, fruits, meats, and dairies. Conditional logistic regression was performed to examine the association between DDS and odds of DN. Anthropometric measures and physical activity levels were evaluated using standard protocols. In a fully adjusted model [controlled for age, body mass index (BMI), energy intake, physical activity, diabetes duration, cardiovascular disease history, and drug usage], greater adherence (the third vs. the first tertile) to DDS [odds ratio (OR) = 0.13; 95% CI (0.05-0.35)], vegetables group [OR = 0.09; 95% CI (0.02-0.36)], and fruits group [OR = 0.05; 95% CI (0.01-0.20)] were significantly associated with lower odds of DN. However, we did not observe any significant relationship between other DDS components and the odds of DN. Our findings showed that higher DDS might be associated with reduced odds of DN. However, more prospective studies are warranted to confirm these findings.Entities:
Keywords: Iran; case-control; diabetic nephropathy; diet variety; dietary diversity score
Year: 2022 PMID: 35433795 PMCID: PMC9012530 DOI: 10.3389/fnut.2022.767415
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Sociodemographic characteristics and anthropometric measures of study participants.
|
|
|
|
|
|---|---|---|---|
| Age (year) |
|
| 0.94 |
| Body mass index (kg/m2) |
|
| 0.06 |
| Diabetes duration (years) |
|
| 0.88 |
| Physical activity | 0.13 | ||
| Low | 31 (29.5) | 37(35.2) | |
| Moderate | 42 (40.0) | 28 (26.7) | |
| High | 32 (30.5) | 40 (38.1) | |
| History of cardiovascular disease | 1.00 | ||
| Yes | 24 (22.9) | 23 (21.9) | |
| No | 81 (77.1) | 82 (78.1) | |
| Angiotensin receptor blockers drug usage | 0.05 | ||
| Yes | 60 (57.1) | 45 (42.9) | |
| No | 45 (42.9) | 60 (57.1) | |
| Angiotensin converting enzyme inhibitors drug usage | 0.001 | ||
| Yes | 44 (41.9) | 21 (20.0) | |
| No | 61 (58.1) | 84 (80.0) | |
| Beta blockers drug usage | 0.72 | ||
| Yes | 20 (19.0) | 18 (17.1) | |
| No | 84 (80.0) | 87 (82.9) | |
| Metformin usage | 1.00 | ||
| Yes | 104 (99.0) | 104 (99.0) | |
| No | 1 (1.0) | 1 (1.0) | |
| Sulfonylureas usage | 0.25 | ||
| Yes | 71 (67.6) | 62 (59.0) | |
| No | 34 (32.4) | 43 (41.0) | |
| Insulin usage | 0.22 | ||
| Yes | 26 (24.8) | 35 (33.3) | |
| No | 79 (75.2) | 70 (66.7) |
Data are presented as mean [standard deviation (SD)] or number (%).
Chi-square test and Fisher's exact test were used for comparison of qualitative variables.
General characteristics and biochemical markers of participants across tertiles of dietary diversity score.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| Age (y) | 54.21 ± 6.88 | 56.52 ± 6.51 | 55.39 ± 7.67 | 0.32 |
| Body weight (kg) | 72.38 ± 11.26 | 72.55 ± 12.29 | 72.55 ± 14.53 | 0.93 |
| Energy (kcal/day) | 1,447.34 ± 240.33 | 1,471.49 ± 366.00 | 1,372.45 ± 241.57 | 0.12 |
| Diabetes duration (y) | 7.84 ± 2.10 | 7.67 ± 2.21 | 7.23 ± 2.22 | 0.10 |
| ACR | 188.10 ± 136.49 | 100.17 ± 127.92 | 88.17 ± 115.55 | <0.001 |
| Albumin (mg/dl) | 13.59 ± 7.37 | 11.21 ± 13.24 | 9.39 ± 8.63 | 0.01 |
| SBP (mmHg) | 125.43 ± 16.94 | 137.55 ± 121.17 | 120.70 ± 16.64 | 0.69 |
| DBP (mmHg) | 83.11 ± 13.60 | 81.54 ± 12.45 | 79.72 ± 11.24 | 0.11 |
| FBS (mg/dl) | 163.47 ± 48.64 | 156.80 ± 53.03 | 161.61 ± 43.09 | 0.82 |
| HB A1c (%) | 8.56 ± 1.27 | 8.21 ± 1.51 | 8.26 ± 1.35 | 0.20 |
| TC (mg/dl) | 186.73 ± 33.66 | 177.36 ± 36.48 | 176.72 ± 36.31 | 0.10 |
| TG (mg/dl) | 176.43 ± 60.73 | 150.29 ± 60.46 | 167.30 ± 62.25 | 0.38 |
| LDL (mg/dl) | 106.43 ± 30.63 | 99.91 ± 31.22 | 95.90 ± 31.21 | 0.04 |
| HDL (mg/dl) | 45.04 ± 7.99 | 46.07 ± 9.26 | 46.01 ± 10.44 | 0.53 |
| Creatinine (mg/dl) | 0.90 ± 0.15 | 0.89 ± 0.19 | 0.90 ± 0.16 | 0.92 |
| BUN (mg/dl) | 15.85 ± 4.95 | 15.01 ± 3.82 | 15.58 ± 3.80 | 0.70 |
| Physical activity | 0.60 | |||
| Low | 24 (34.3) | 18 (26.1) | 26 (36.6) | |
| Moderate | 25 (35.7) | 25 (36.2) | 20 (28.2) | |
| High | 21 (30.0) | 26 (37.7) | 25 (35.2) | |
| CVD history (%) | 14 (20.0) | 15 (21.7) | 18 (25.4) | 0.75 |
| ARB drugs user (%) | 35 (50.0) | 31 (44.9) | 39 (54.9) | 0.50 |
| ACEI drugs user (%) | 21 (30.0) | 22 (31.9) | 22 (31.0) | 0.98 |
| Beta-blocker drugs user (%) | 13 (18.6) | 15(21.7) | 10 (14.1) | 0.50 |
| Metformin user (%) | 70 (100.0) | 67 (97.1) | 71 (100.0) | 0.11 |
| Sulfonylurea drugs user (%) | 45 (64.3) | 43 (62.3) | 45 (63.4) | 0.98 |
| Insulin user (%) | 20 (28.6) | 23 (33.3) | 18 (25.4) | 0.59 |
BMI, body mass index; ACR, albumin creatinine ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HB, hemoglobin; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; blood urine nitrogen; CVD, cardiovascular disease; ARB, angiotensin receptor blockers; ACIE, angiotensin-converting enzyme inhibitors.
Data are presented as mean ± SD or number (percent).
ANOVA test was used.
Chi-square test was used.
Dietary intakes of participants across tertiles of dietary diversity score.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| Protein (gr/day) | 47.35 ± 0.56 | 46.37 ± 0.57 | 47.23 ± 0.56 | 0.41 |
| Carbohydrate (gr/day) | 250.01 ± 1.78 | 254.96 ± 1.80 | 249.01 ± 1.78 | 0.04 |
| Total fat (gr/day) | 33.11 ± 0.68 | 31.86 ± 0.69 | 33.91 ± 0.68 | 0.11 |
| Cholesterol (mg/day) | 4.58 ± 0.82 | 8.97 ± 0.83 | 6.69 ± 0.82 | 0.001 |
| Saturated fat (gr/day) | 6.16 ± 0.14 | 6.03 ± 0.14 | 6.43 ± 0.14 | 0.11 |
| Vitamin A (RAE/day) | 38.58 ± 2.07 | 38.54 ± 2.09 | 41.74 ± 2.07 | 0.46 |
| Vitamin K (μg/day) | 13.71 ± 0.52 | 12.23 ± 0.52 | 13.30 ± 0.52 | 0.12 |
| Vitamin E (mg/day) | 4.02 ± 0.13 | 4.35 ± 0.13 | 3.85 ± 0.13 | 0.02 |
| Vitamin C (mg/day) | 10.69 ± 0.63 | 11.67 ± 0.64 | 8.88 ± 0.63 | 0.01 |
| Vitamin B1 (mg/day) | 1.76 ± 0.03 | 1.64 ± 0.03 | 1.67 ± 0.03 | 0.003 |
| Vitamin B2 (mg/day) | 1.02 ± 0.01 | 0.93 ± 0.01 | 0.96 ± 0.01 | <0.001 |
| Vitamin B3 (mg/day) | 16.75 ± 0.22 | 15.69 ± 0.22 | 15.75 ± 0.22 | 0.001 |
| Vitamin B5 (mg/day) | 2.59 ± 0.07 | 2.47 ± 0.07 | 2.32 ± 0.07 | 0.02 |
| Vitamin B6 (mg/day) | 0.77 ± 0.01 | 0.76 ± 0.01 | 0.77 ± 0.01 | 0.85 |
| Vitamin B9 (μg/day) | 412.87 ± 8.47 | 368.23 ± 8.56 | 370.88 ± 8.47 | <0.001 |
| Vitamin B12 (μg/day) | 0.11 ± 0.01 | 0.18 ± 0.01 | 0.15 ± 0.01 | 0.01 |
| Sodium (mg/day) | 3,811.36 ± 112.47 | 3,162.67 ± 113.61 | 3,595.04 ± 112.37 | <0.001 |
| Potassium (mg/day) | 1,722.02 ± 36.15 | 1,684.84 ± 36.51 | 1,716.07 ± 36.12 | 0.74 |
| Calcium (mg/day) | 404.56 ± 5.10 | 391.06 ± 5.15 | 415.61 ± 5.10 | 0.004 |
| Iron (mg/day) | 15.20 ± 0.14 | 14.59 ± 0.14 | 14.90 ± 0.14 | 0.009 |
| Phosphorous (mg/day) | 930.83 ± 13.60 | 891.86 ± 13.73 | 897.76 ± 13.58 | 0.09 |
| Magnesium (mg/day) | 361.52 ± 7.39 | 339.61 ± 7.46 | 365.52 ± 7.38 | 0.03 |
| Zinc (mg/day) | 8.08 ± 0.23 | 7.85 ± 0.23 | 8.63 ± 0.23 | 0.04 |
Data are presented as mean ± SE (except for energy intake that presented as mean ± SD).
ANCOVA test was used.
Conditional logistic regression models for odds of diabetic nephropathy according to total dietary diversity score and variety within the food groups.
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
|
| ||||
| Tertile 1 (<4.42) | 53/17 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Tertile 2 (≥4.42– <5.51) | 26/43 | 0.19 (0.08–0.43) | 0.15 (0.06–0.39) | 0.10 (0.03–0.33) |
| Tertile 3 (≥5.51) | 26/45 | 0.24 (0.11–0.49) | 0.21 (0.10–0.46) | 0.13 (0.05–0.35) |
| <0.001 | <0.001 | <0.001 | ||
|
| ||||
| Category 1 (≤0.5) | 11/12 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Category 2 (>0.5– ≤ 1.0) | 25/54 | 0.41 (0.15–1.12) | 0.28 (0.09–0.86) | 0.40 (0.11–1.54) |
| Category 3 (>1.0) | 69/39 | 2.03 (0.80–5.13) | 1.52 (0.54–4.29) | 3.14 (0.82–12.07) |
| 0.003 | 0.008 | 0.002 | ||
|
| ||||
| Category 1 (≤0.5) | 45/15 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Category 2 (>0.5– ≤ 1.0) | 47/45 | 0.40 (0.19–0.85) | 0.34 (0.15–0.79) | 0.22 (0.07–0.66) |
| Category 3 (>1.0) | 13/45 | 0.13 (0.05–0.31) | 0.10 (0.04–0.26) | 0.05 (0.01–0.20) |
| <0.001 | <0.001 | <0.001 | ||
|
| ||||
| Category 1 (≤0.5) | 18/24 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Category 2 (>0.5– ≤ 1.0) | 39/26 | 1.86 (0.87–3.98) | 1.92 (0.86–4.29) | 1.86 (0.72–4.80) |
| Category 3 (>1.0) | 48/55 | 1.15 (0.57–2.34) | 1.19 (0.56–2.52) | 0.97 (0.41–2.33) |
| 0.93 | 0.91 | 0.47 | ||
|
| ||||
| Category 1 (≤0.5) | 26/5 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Category 2 (>0.5– ≤ 1.0) | 46/26 | 0.44 (0.15–1.27) | 0.36 (0.12–1.10) | 0.45 (0.11–1.91) |
| Category 3 (>1.0) | 33/74 | 0.13 (0.05–0.37) | 0.12 (0.04–0.34) | 0.09 (0.02–0.36) |
| <0.001 | <0.001 | <0.001 | ||
|
| ||||
| Category 1 (≤0.5) | 41/29 | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| Category 2 (>0.5– ≤ 1.0) | 32/47 | 0.40 (0.19–0.86) | 0.35 (0.15–0.82) | 0.26 (0.08–0.78) |
| Category 3 (>1.0) | 32/29 | 0.76 (0.38–1.53) | 0.77 (0.36–1.63) | 0.61 (0.24–1.52) |
| 0.44 | 0.50 | 0.26 | ||
Conditional logistic regression was used.
Data are presented as odds ratio [95% confidence interval (CI)].
Crude: Unadjusted model.
Model 1: Adjusted for age, body mass index, energy intake, and physical activity.
Model 2: Adjusted for confounders in model 1 plus diabetes duration, cardiovascular diseases history, and drug usage (angiotensin receptor blockers; angiotensin-converting enzyme inhibitors, beta-blockers, metformin, sulphonylurea, and insulin).